

# Dimitrios Sagris

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/793185/publications.pdf>

Version: 2024-02-01

30  
papers

383  
citations

1040056

9  
h-index

839539

18  
g-index

30  
all docs

30  
docs citations

30  
times ranked

355  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anticoagulation for stroke prevention after embolic stroke of undetermined source of presumably cardiac source: The sail to Ithaca. <i>European Journal of Internal Medicine</i> , 2022, 95, 42-43.	2.2	0
2	Immunity, Vascular Aging and Stroke. <i>Current Medicinal Chemistry</i> , 2022, 29, 5510-5521.	2.4	7
3	Interleukin-6 inhibitors reduce mortality in coronavirus disease-2019: An individual patient data meta-analysis from randomized controlled trials. <i>European Journal of Internal Medicine</i> , 2022, 101, 41-48.	2.2	12
4	Measurement of Midregional Pro-Atrial Natriuretic Peptide to Discover Atrial Fibrillation in Patients With Ischemic Stroke. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1369-1381.	2.8	17
5	Recurrent Ischemic Stroke and Bleeding in Patients With Atrial Fibrillation Who Suffered an Acute Stroke While on Treatment With Nonvitamin K Antagonist Oral Anticoagulants: The RENO-EXTEND Study. <i>Stroke</i> , 2022, 53, 2620-2627.	2.0	28
6	Atrial fibrillation, a contemporary sign of multimorbidity and irregular social inequity. <i>Lancet Regional Health - Europe</i> , The, 2022, 17, 100395.	5.6	3
7	Long-Term Cardiac Monitoring After Embolic Stroke of Undetermined Source: Search Longer, Look Harder. <i>American Journal of Medicine</i> , 2022, 135, e311-e317.	1.5	5
8	Clopidogrel Monotherapy versus Aspirin Monotherapy in Patients with Established Cardiovascular Disease: Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1879-1887.	3.4	5
9	Sinus rhythm restoration and improved outcomes in patients with acute ischemic stroke and in-hospital paroxysmal atrial fibrillation. <i>European Stroke Journal</i> , 2022, 7, 421-430.	5.5	5
10	Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: A clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. <i>International Journal of Stroke</i> , 2021, 16, 738-750.	5.9	11
11	Carotid Atherosclerosis and Patent Foramen Ovale in Embolic Stroke of Undetermined Source. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105409.	1.6	11
12	Atrial Cardiopathy and Likely Pathogenic Patent Foramen Ovale in Embolic Stroke of Undetermined Source. <i>Thrombosis and Haemostasis</i> , 2021, 121, 361-365.	3.4	7
13	Atrial fibrillation and cognitive decline: it takes more than an irregular heart beat, to beat the brain. <i>Age and Ageing</i> , 2021, 50, 1891-1893.	1.6	1
14	Adherence to oral anticoagulation in ischemic stroke patients with atrial fibrillation. <i>Annals of Medicine</i> , 2021, 53, 1613-1620.	3.8	9
15	Proprotein Convertase Subtilisin-Kexin Type 9 inhibitors and stroke prevention: A meta-analysis. <i>European Journal of Internal Medicine</i> , 2021, 85, 130-132.	2.2	7
16	Statin treatment and outcomes after embolic stroke of undetermined source. <i>Internal and Emergency Medicine</i> , 2021, 16, 1261-1266.	2.0	5
17	Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. <i>Stroke</i> , 2021, 52, 1450-1454.	2.0	7
18	Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature. <i>Frontiers in Neurology</i> , 2021, 12, 666086.	2.4	10

#	ARTICLE	IF	CITATIONS
19	Validation of the AF-ESUS score to identify patients with embolic stroke of undetermined source and low risk of device-detected atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2021, 89, 135-136.	2.2	12
20	COVID-19 and ischemic stroke. <i>European Journal of Neurology</i> , 2021, 28, 3826-3836.	3.3	55
21	Machine-Learning-Derived Model for the Stratification of Cardiovascular risk in Patients with Ischemic Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 106018.	1.6	4
22	Dabigatran Reversal With Idarucizumab and In-Hospital Mortality in Intracranial Hemorrhage: A Systematic Review of Real-Life Data From Case Reports and Case Series. <i>Frontiers in Neurology</i> , 2021, 12, 727403.	2.4	1
23	Atrial High-Rate Episode Duration Thresholds and Thromboembolic Risk: A Systematic Review and Meta-Analysis. <i>Journal of the American Heart Association</i> , 2021, 10, e022487.	3.7	17
24	Response by Sagris et al to Letter Regarding Article, "Antithrombotic Treatment in Cryptogenic Stroke Patients With Patent Foramen Ovale: Systematic Review and Meta-Analysis". <i>Stroke</i> , 2020, 51, e39.	2.0	0
25	Bleeding risk comparison between direct oral anticoagulants at doses approved for atrial fibrillation and aspirin: systematic review, meta-analysis and meta-regression. <i>European Journal of Internal Medicine</i> , 2020, 79, 31-36.	2.2	8
26	Characteristics and outcomes of Embolic Stroke of Undetermined Source according to stroke severity. <i>International Journal of Stroke</i> , 2020, 15, 866-871.	5.9	6
27	Antithrombotic treatment in patients with stroke and supracardiac atherosclerosis. <i>Neurology</i> , 2020, 95, e499-e507.	1.1	7
28	Antithrombotic Treatment in Cryptogenic Stroke Patients With Patent Foramen Ovale. <i>Stroke</i> , 2019, 50, 3135-3140.	2.0	16
29	20-year trends of characteristics and outcomes of stroke patients with atrial fibrillation. <i>International Journal of Stroke</i> , 2018, 13, 707-716.	5.9	8
30	Closure of Patent Foramen Ovale Versus Medical Therapy in Patients With Cryptogenic Stroke or Transient Ischemic Attack. <i>Stroke</i> , 2018, 49, 412-418.	2.0	99